Abstract
The ubiquitin-conjugating enzyme CDC34 (UBC3) is linked to cell cycle progression in diverse cell types; however, its role in multiple myeloma (MM) pathogenesis is unclear. Here, we show that CDC34 is highly expressed in patient MM cells and MM cell lines versus normal cells. Blocking CDC34 using a dominant-negative strategy enhances the anti-MM activity of Bortezomib/Proteasome inhibitor PS-341, dexamethasone (Dex) and 2-Methoxyestradiol (2ME2). The expression of wild-type CDC34 reduces Dex-induced cytotoxicity in MM cells. Moreover, inhibition of CDC34 enzymatic activity abrogates interleukin-6-induced protection against Dex-induced apoptosis. Together, these findings provide evidence that (1) CDC34 expression is associated with growth and survival of MM cells and (2) blocking CDC34 activity not only enhances anti-MM activity of Bortezomib and 2ME2 but also overcomes IL-6-triggered Dex-resistance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- MM:
-
multiple myeloma
- 2ME2:
-
2-Methoxyestradiol
- Dex:
-
dexamethasone
References
Block K, Boyer TG and Yew PR . (2001). J. Biol. Chem., 276, 41049–41058.
Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N and Anderson KC . (2002). Blood, 100, 2187–2194.
Chauhan D, Hideshima T, Pandey P, Treon S, Teoh G, Raje N, Rosen S, Krett N, Husson H, Avraham S, Kharbanda S and Anderson KC . (1999). Oncogene, 18, 6733–6740.
Chauhan D, Hideshima T, Rosen S, Reed JC, Kharbanda S and Anderson KC . (2001). J. Biol. Chem., 276, 24453–24456.
Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW and Anderson KC . (1997). Blood, 89, 227–234.
Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W and Anderson KC . (2003a). Blood, 101, 3606–3614.
Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringharpure R, Burger R, Munshi N, Ohtake Y, Saxena S and Anderson KC . (2003b). Blood, 102, 3379.
Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Munshi N, Kharbanda S and Anderson KC . (2003c). J. Biol. Chem., 278, 17593–17596.
Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, Kharbanda S and Anderson KC . (2000). J. Biol. Chem., 275, 27845–27850.
Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA and Anderson KC . (1996). Blood, 87, 1104–1112.
Chen YH, Desai P, Shiao RT, Lavelle D, Haleem A and Chen J . (1996). Blood, 87, 314–323.
De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, Pellet F, Pantesco V, Reme T, Jourdan M, Rossi JF, Orntoft T and Klein B . (2002). Oncogene, 21, 6848–6857.
Desnoyers S, Shah GM, Brochu G and Poirier GG . (1994). Anal. Biochem., 218, 470–473.
Eliseeva E, Pati D, Diccinanni MB, Yu AL, Mohsin SK, Margolin JF and Plon SE . (2001). Cell Growth Differ., 12, 427–433.
Goebl MG, Yochem J, Jentsch S, McGrath JP, Varshavsky A and Byers B . (1988). Science, 241, 1331–1335.
Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H and Epstein J . (1994). Blood, 84, 3063–3070.
Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI and Anderson KC . (2000). Blood, 96, 2943–2950.
Hwang GW, Furuchi T and Naganuma A . (2002). FASEB J., 16, 709–711.
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG . (1993). Cancer Res., 53, 3976–3985.
Li YZ, Li CJ, Pinto AV and Pardee AB . (1999). Mol. Med., 5, 232–239.
Moalli PA, Pillay S, Weiner D, Leikin R and Rosen ST . (1992). Blood, 79, 213–222.
Rowley M, Liu P and Van Ness B . (2000). Blood, 96, 3175–3180.
Tanaka K, Kondoh N, Shuda M, Matsubara O, Imazeki N, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T, Horiuchi S, Yamamoto N and Yamamoto M . (2001). Biochim. Biophys. Acta, 1536, 1–12.
Verma R, Feldman RM and Deshaies RJ . (1997). Mol. Biol. Cell, 8, 1427–1437.
Yew PR and Kirschner MW . (1997). Science, 277, 1672–1676.
Acknowledgements
This investigation was supported by NIH Grants RO-1 CA 50947, PO-1 CA 78373, and IP50CA10070, a Doris Duke Distinguished Clinical Research Scientist Award (KCA), The Myeloma Research Fund, and The Cure Myeloma Fund.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chauhan, D., Li, G., Hideshima, T. et al. Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene 23, 3597–3602 (2004). https://doi.org/10.1038/sj.onc.1207458
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207458
Keywords
This article is cited by
-
Structural insights into E1 recognition and the ubiquitin-conjugating activity of the E2 enzyme Cdc34
Nature Communications (2019)
-
The Catalytically Inactive Mutation of the Ubiquitin-Conjugating Enzyme CDC34 Affects its Stability and Cell Proliferation
The Protein Journal (2018)
-
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth
Gene Therapy (2008)
-
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Nature Reviews Cancer (2007)
-
Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines
International Journal of Hematology (2007)